Janus Henderson Investors is a British-American global asset management group headquartered in London, offering equities, fixed income, multi-asset, and alternatives strategies to individual, intermediary, and institutional investors worldwide. Founded in 1934, the firm manages assets across public and private markets including private equity and private credit in emerging markets.
60% of their portfolio is in Biotech & Life Sciences. Deal activity increased 167% year-over-year (8 deals in the last 12 months). Their most common stage is series-b (40% of deals). Average disclosed round size is $127.4M (across 37 rounds with reported amounts).
Portfolio
38
Fund Size
—
Top Stage
Series B
Last 12 Mo
8
Team
Andrew Forman
Associate Portfolio Manager | Money Market Analyst
John King
Associate Portfolio Manager
Agustin Mohedas, PhD
Portfolio Manager | Research Analyst
Cody Wheaton, CFA
Portfolio Manager | Research Analyst
Daniel Lyons, PhD, CFA
Portfolio Manager | Research Analyst
Dillan Shah, CFA
Quantitative Research Analyst
Douglas Turnbull, CFA
Portfolio Manager | Research Analyst
Edward Su, CFA
Portfolio Manager | Research Analyst
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Triveni Bio | Series C | $65M | Oct 2026 |
 OMass Therapeutics | Series C | $310M | Oct 2026 |
 Vyne Therapeutics | Unknown | $200M | Jul 2026 |
 Lycia Therapeutics | Series D | $75M | Jun 2026 |
 Circle | Series F | $400M | May 2026 |
 Windward Bio | Unknown | $165M | May 2026 |
 Windward | Unknown | $165M | May 2026 |
 Ray Therapeutics | Series B | $125M | Apr 2026 |
 Think Bioscience | Series A | $55M | Jan 2026 |
 Ovid Therapeutics Inc. | Bridge | $60M | Jan 2026 |
 Diagonal Therapeutics | Series B | $125M | Jan 2026 |
 BlossomHill Therapeutics | Series B | $84M | Dec 2025 |
| CCurevo Vaccine | Series B | $110M | Mar 2025 |
| Ovid Therapeutics Inc. | Series A | — | Jan 2025 |
 Ottimo Pharma | Series A | $140M | Dec 2024 |
| OOttimo | Series A | $140M | Dec 2024 |
 Ventyx Biosciences | Series A | $27M | Sep 2024 |
 Obsidian Therapeutics | Series C | $160.5M | Apr 2024 |
 ProfoundBio | Series B | $112M | Feb 2024 |
 Asher Bio | Series C | $55M | Jan 2024 |
| AAsher Biotherapeutics | Series C | $55M | Jan 2024 |
 ShouTi | Series B | $100M | Jan 2022 |
 Quell | Unknown | $156M | Nov 2021 |
 Nuvalent | Series B | $135M | May 2021 |
 Tyra | Series B | $106M | Mar 2021 |
Top Co-Investors
Last updated: 20 October 2026